What are the regulatory considerations regarding the use of rivaroxaban for nonvalvular atrial fibrillation?
Rivaroxaban has been evaluated for nonvalvular atrial fibrillation in several studies, including Connolly et al’s 2011 study, “Evaluating rivaroxaban for nonvalvu- lar atrial fibrillation: regulatory considerations”, published in the New England Journal of Medicine. This study found that rivaroxaban was generally safe and effective, with a lower risk of bleeding compared to warfarin and a similar risk of ischemic stroke. Other studies, such as those by Granger et al (2011) and Diener et al (2012) have also examined the efficacy of rivaroxaban in patients with atrial fibrillation and previous stroke or transient ischemic attack. Based on the results of these studies, it is suggested that rivaroxaban is an effective and safe treatment option for nonvalvular atrial fibrillation.  